Tag: excess profits
The Pharmaceutical Accountability Foundation faces AbbVie in Court for the first time in its Humira pricing case
Rosalind Turkie -
AMSTERDAM, THE NETHERLANDS: In February of 2023, the Pharmaceutical Accountability Foundation (PAF) brought a lawsuit against the company on the grounds that AbbVie had...
Version 15 November 2023
About Adalimumab/Humira and pricing issues
AbbVie’s blockbuster drug Adalimumab (brand name: Humira) for the treatment of rheumatoid arthritis is one of the...
AbbVie overcharged the Dutch health care system by as much as €1.2 billion for Humira
Rosalind Turkie -
AMSTERDAM, THE NETHERLANDS: The Pharmaceutical Accountability Foundation (PAF) today brought a lawsuit against pharmaceutical company AbbVie for unfair, excessive pricing practices on its blockbuster...
Licensed under Creative Commons (CC BY-NC-SA 4.0), The Pharmaceutical Accountability Foundation 2022


